Reduction of COVID 19 Transmission to Health Care Professionals

COVID 19 Clinical Trial

Official title:

Reduction of COVID 19 Transmission to Health Care Professionals

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04462627
• Other study ID #: CHUB-BDS-COVID19
• Status: Completed
• Phase: N/A
• Start date: April 14, 2020
• Est. completion date: April 11, 2022

Study information

• Verified date: July 2022
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

When the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate.

The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an "secreting" individual, the antigens of the "ABO" system of the infected individual will be present on the surface of the viruses formed in his/her lungs.

It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the "ABO" system carried by the virus. A patient of group "O" would thus defend himself much better against a virus carrying antigens of blood group "A", the natural antibodies "anti-A" of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups.

In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the "ABO" and "Lewis" blood groups of patients and "ABO" of nursing staff in health care units, if operational and human conditions allow.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 566
• Est. completion date: April 11, 2022
• Est. primary completion date: April 11, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• COVID19 positive patients admitted within the CHU Brugmann Hospital

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• COVID 19
• COVID-19

Intervention

Diagnostic Test:
• Blood group determination
Determination of the blood group (ABO/LE)
• Antibody titration
Natural anti-A and anti-B antibody levels will be determined by a gel agglutination technique on the Biorad IH-500 automaton.

Dietary Supplement:
• Probiotic
Administration of a probiotic to healthy volunteers to determine if it increases the level of circulating natural anti-A and anti-B antibodies (Probactiol Plus (Metagenics)).

Locations

Country	Name	City	State
Belgium	CHU Brugmann	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Hanane EL KENZ

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anti-A antibody concentration	Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	baseline
Primary	Anti-A antibody concentration	Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	Day 4
Primary	Anti-A antibody concentration	Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	Week 1
Primary	Anti-A antibody concentration	Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	Week 2
Primary	Anti-A antibody concentration	Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	Week 3
Primary	Anti-B antibody concentration	Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	baseline
Primary	Anti-B antibody concentration	Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	Day 4
Primary	Anti-B antibody concentration	Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	Week 1
Primary	Anti-B antibody concentration	Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	Week 2
Primary	Anti-B antibody concentration	Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.	Week 3
Primary	Blood group	Blood group (ABO/LE)	baseline